Skip to content

FrontlightResearch

Institution

Hospital Universitario Reina Sofía

Cordova, SpainhealthcareWebsite

Also known as: Hospital Universitario Reina Sofía · Reina Sofia Hospital

269running trials
125closed trials
0trials confirmed by the site in the last 60 days
–languages not stated

The site has not confirmed any trial yet.

Running trials

Not yet recruiting
A study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)
2026-525757-37-00· PHASE3· Source
Not yet recruiting
A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)
2026-525755-82-00· PHASE3· Source
Recruiting
Evaluation of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)
2025-523288-39-00· PHASE2· Source
Not yet recruiting
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
NCT07861100· PHASE3· Source
Recruiting
A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
NCT07412704· PHASE1 PHASE2· Source
Not yet recruiting
Phase 3 Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC 6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
2025-524969-24-00· PHASE3· Source
Not yet recruiting
Clinical trial to assess the efficacy and safety of a vaccine for olive pollen allergy
2026-526390-41-00· PHASE3· Source
Recruiting
A TWO-STAGE, SINGLE-ARM, PHASE II STUDY OF ZONGERTINIB PLUS FULVESTRANT IN PARTICIPANTS WITH HORMONE RECEPTOR-POSITIVE/HER2- NEGATIVE ADVANCED BREAST CANCER HARBORING HER2 MUTATIONS (AGATHA)
2026-525328-10-00· PHASE2· Source
Recruiting
A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tumour location (right-PTL) - ARIEL-ENGIC 04 EU trial
2025-521209-42-00· PHASE4· Source
Recruiting
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
NCT07711002· PHASE3· Source
Not yet recruiting
A Phase 2, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of CRD-4730 in patients with heart failure with reduced ejection fraction (HFREF) (CALIBRATE-HF)
2025-525033-31-00· PHASE2· Source
Recruiting
Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer
NCT07473128· PHASE3· Source
Recruiting
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993· PHASE3· Source
Not yet recruiting
A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer
NCT07340658· PHASE3· Source
Recruiting
A Study to Evaluate Targeted Therapies for Patients with Rheumatoid Arthritis
2025-523127-21-00· PHASE1· Source
Recruiting
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
2025-523670-17-00· PHASE3· Source
Recruiting
A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma
2025-523815-12-00· PHASE3· Source
Recruiting
A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed
NCT07650916· PHASE3· Source
Recruiting
Grass/Olive Immunotherapy for Rhinitis and Asthma (GOES)
2025-521709-42-00· PHASE3· Source
Recruiting
A study to evaluate the safety and efficacy of oral decitabine plus ivosidenib in newly diagnosed adult patients with acute myeloid leukemia older than 60 years and/or inelegible for standard induction chemotherapy
2025-523238-17-00· PHASE2· Source
Recruiting
A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)
NCT07652736· Source
Recruiting
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)
2025-521587-35-00· PHASE3· Source
Recruiting
An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis
NCT07620392· PHASE2· Source
Recruiting
Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC
NCT07018947· PHASE2· Source
Recruiting
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
NCT07192952· PHASE3· Source
Not yet recruiting
Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma
NCT07593040· PHASE2· Source
Recruiting
Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer
NCT06783491· PHASE3· Source
Recruiting
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
NCT07525206· PHASE3· Source
Recruiting
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
NCT07566156· PHASE3· Source
Recruiting
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
NCT07549412· PHASE3· Source
Recruiting
A study to compare Venetoclax Azacitidine and Quizartinib Vs Venetoclax and Azacitidine in newly diagnosed acute myeloid leukemia patient´s ineligible for standard induction chemotherapy
2025-522979-29-00· PHASE3· Source
Recruiting
Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER)
NCT07611747· PHASE4· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
NCT07227311· PHASE2· Source
Recruiting
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
NCT07355218· PHASE3· Source
Recruiting
Study on Prostate Salvage Using High-dose-rate Brachytherapy
NCT07860528· Source
Recruiting
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07287150· PHASE2· Source
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445· PHASE3· Source
Not yet recruiting
Treatment for Ph-negative ALL for Adults up to 65 Years
NCT07443592· Source
Not yet recruiting
Radiofrequency Ablation Multicenter Observational Study in Renal Oncology Patients
NCT07465458· Source
Recruiting
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
NCT07404865· PHASE3· Source
Recruiting
Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy
NCT07340164· PHASE2· Source
Recruiting
A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
NCT07047690· PHASE2· Source
Recruiting
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
NCT07318558· PHASE3· Source
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
NCT07216703· PHASE3· Source
Recruiting
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
NCT07195682· PHASE1· Source
Active, not recruiting
A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
NCT07223697· PHASE2· Source
Recruiting
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
NCT07218809· PHASE3· Source
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380· PHASE3· Source
Recruiting
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
NCT07221188· PHASE3· Source
Recruiting
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
NCT07222800· PHASE3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Colorectal cancer16 recruiting
Prostate cancer11 recruiting
Ovarian cancer10 recruiting
Lung cancer9 recruiting
Bladder cancer8 recruiting
Heart failure8 recruiting
Rheumatoid arthritis8 recruiting
Fatty liver disease (MASLD/MASH)7 recruiting
Kidney cancer7 recruiting
Crohn's disease6 recruiting
Lupus (SLE)6 recruiting
Pancreatic cancer6 recruiting
Childhood cancers5 recruiting
Chronic lymphocytic leukaemia5 recruiting
Endometrial cancer5 recruiting
Liver and biliary tract cancer5 recruiting
Metastatic breast cancer5 recruiting
Ulcerative colitis5 recruiting
Gastric and esophageal cancer4 recruiting
Multiple myeloma4 recruiting
Obesity4 recruiting
Systemic sclerosis (scleroderma)4 recruiting
Acute myeloid leukemia3 recruiting
Asthma3 recruiting
Triple-negative breast cancer3 recruiting
Ankylosing spondylitis2 recruiting
Cervical cancer2 recruiting
Chronic kidney disease2 recruiting
Coronary artery disease2 recruiting
HIV2 recruiting
Myasthenia gravis2 recruiting
Acute lymphoblastic leukaemia1 recruiting
Amyloidosis1 recruiting
Atopic dermatitis (eczema)1 recruiting
Chronic myeloid leukaemia1 recruiting
CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
Follicular lymphoma1 recruiting
High blood pressure1 recruiting
Mantle cell lymphoma1 recruiting
Melanoma1 recruiting
Multiple sclerosis1 recruiting
Primary biliary cholangitis1 recruiting
Psoriasis1 recruiting
Psoriatic arthritis1 recruiting
Sjögren's disease1 recruiting
Type 2 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

Completed
ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion
NCT05225961· PHASE4· Source
Recruiting
A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease
2024-516966-12-00· PHASE2· Source
Active, not recruiting
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)
NCT07234942· PHASE1· Source
Completed
A Study Evaluating BFB759 in Atopic Dermatitis
2025-521624-30-00· PHASE2· Source
Completed
A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis.
2023-507705-34-00· PHASE3· Source
Active, not recruiting
Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced NSCLC (Substudy NSCLC)
2024-517818-15-00· PHASE1 PHASE2· Source
Active, not recruiting
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
NCT06726265· PHASE3· Source
Active, not recruiting
A Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in Participants living with Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection on Antiretroviral Treatment
2023-509588-25-00· PHASE2· Source
Completed
KISIMA-02 vaccine-based immunotherapy for patients with pancreatic cancer
NCT05846516· PHASE1· Source
Completed
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia
2024-511057-22-00· PHASE3· Source
Recruiting
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
NCT06717698· PHASE2· Source
Completed
Effect of Copper CU64 PSMA I&T scanning to detect potential disease spread to lymph nodes in men with newly diagnosed Prostate Cancer
2024-512754-16-01· PHASE3· Source
Recruiting
A Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients
NCT06578078· PHASE3· Source
Completed
Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from Olea europaea pollen allergy
2024-511383-88-00· PHASE2 PHASE3· Source
Completed
A study to compare efficacy, safety, and immune response of GME751 and EU-authorized Keytruda in adult participants with untreated metastatic lung cancer
2023-506882-70-00· PHASE3· Source
Completed
A Retrospective Chart Review Study of Patients With CLAD-BOS Post Lung Transplantation
NCT06503770· Source
Recruiting
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
NCT06056297· PHASE3· Source
Completed
A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding study to evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GSK1070806 SC injection in Adult Participants with Moderate to Severe Atopic Dermatitis
NCT05999799· PHASE2· Source
Completed
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis
2023-504564-42-00· PHASE2· Source
Completed
Regorafenib-pembrolizumab vs. TACE/TARE in intermediate-stage HCC beyond up-to-7.
NCT04777851· PHASE3· Source
Completed
Study to Assess the Safety, Tolerability and Efficacy of Lurbinectedin and Dostarlimab treatment in patients with endometrial cancer after disease progression to a previous treatment with Platinum-based Chemotherapy. LiDer trial
2023-508583-30-00· PHASE1 PHASE2· Source
Completed
A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension
NCT06168409· PHASE3· Source
Completed
A study to investigate the effect of different doses of AZD0780 on low-density lipoprotein cholesterol (LDL-C) levels compared with placebo and its safety and tolerability in participants 18 to 75 years of age with dyslipidemia
2023-506197-12-00· PHASE2· Source
Completed
Single-dose Study of BMS-986326 at Two Dose Levels in Participants with Atopic Dermatitis
2022-502997-18-00· PHASE1· Source
Completed
A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity
NCT06104124· PHASE3· Source
Completed
Multicenter Phase 2 study to evaluate the efficacy and safety of Cetuximab in combination with Encorafenib plus Binimetinib as induction treatment in BRAF (V600E) mutated MSS, initially resectable or potentially resectable advanced colorectal cancer: CEBBRA study.
2022-502413-29-00· PHASE2· Source
Active, not recruiting
A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus
NCT05835986· PHASE1· Source
Completed
Developing a Screening Tool for Interstitial Lung Disease in People With Rheumatoid Arthritis Using Risk Factors
NCT05855109· Source
Completed
Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension
NCT06153693· PHASE3· Source
Active, not recruiting
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
NCT06136741· PHASE2· Source
Completed
A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD (ROCKET-ASCEND)
NCT05882877· PHASE3· Source
Active, not recruiting
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
NCT06047444· PHASE3· Source
Completed
A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus
NCT06013995· PHASE1· Source
Completed
A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis
NCT05923099· PHASE2· Source
Completed
A Study to Evaluate the Impact of Liquid Biopsy in Participants With a Clinical Diagnosis of Advanced Cancer
NCT05846594· Source
Completed
Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)
NCT05882734· PHASE1 PHASE2· Source
Completed
A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy
NCT05958407· PHASE3· Source
Completed
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
NCT05931367· PHASE3· Source
Completed
A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)
NCT05798520· PHASE2· Source
Completed
ZN-c3 in Adult Participants With Metastatic Colorectal Cancer
2022-502267-37-00· PHASE1 PHASE2· Source
Active, not recruiting
Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension
NCT05968430· PHASE3· Source
Active, not recruiting
Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
NCT05883644· PHASE3· Source
Completed
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
NCT05882045· PHASE3· Source
Completed
A study in metastatic breast cancer patients receiving eftilagimod alpha or placebo in combination with a standard chemotherapy (paclitaxel)
NCT05747794· PHASE2 PHASE3· Source
Completed
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
NCT05805501· PHASE2· Source
Completed
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
NCT05803421· PHASE3· Source
Completed
OptimiZation Of Lipid Lowering Therapies Using a Decision Support System In Patients With Acute Coronary Syndrome.
NCT05844566· Source
Completed
A Open-label Study to Evaluate the Efficacy, Safety, Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis
NCT04781543· PHASE2· Source
Active, not recruiting
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034· PHASE3· Source
Completed
A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)
NCT05694260· PHASE2· Source

Trial sites

Hospital Universitario Reina Sofia395 trials
Reina Sofía Hospital0 trials
Hospital Universitario Reina Sofía0 trials
Hospital Universitario Reina Sofía2 trials

Conditions

Diseases this institution publishes on or runs trials for.

Ulcerative colitis69 works · 11 trials
Crohn's disease67 works · 10 trials
Rheumatoid arthritis49 works · 11 trials
Psoriatic arthritis40 works · 8 trials
Ankylosing spondylitis26 works · 4 trials
Neuroendocrine tumours9 works · 1 trials

Institution data: ROR 02vtd2q19 (CC0-1.0)Updated 3 Nov 2026

Report an error